Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
The intersection of health and technology is revving up. Exciting new developments to improve care across the board — from clinical trials to at-home diagnostics and treatments — seemingly come to light on a daily basis. As we discuss in this month’s cover story, healthcare is the focus of extensive development in terms of health management apps, telemedicine platforms, AI diagnosis, and the use of video, mobile apps, text messaging, sensors and social media, and more.
Pharmaceutical companies are investing significant resources to explore the potential of virtual health. Granted, many of these efforts are still in early-stage or pilot program implementation, but the excitement around the potential benefits is encouraging. Experts note that recent digital transformation trends provide both patients and companies with unparalleled access to information surrounding the impact of a healthcare strategy or pharmaceutical product, and the influence of this on patients’ overall well-being and everyday life could be immeasurable.
Therefore, it’s no surprise that pharmaceutical company partnerships between technology and data companies to discover ways to best use virtual health and how it can improve processes across all business operations are also on the rise.
As noted, on the pharma level, virtual health tools will enable the industry to have broader engagement with patients and physicians along multiple touchpoints. From digital tools to help solve problems associated with clinical trials to enhancing R&D, the life-sciences industry is significantly investing in virtual health tools, such as artificial intelligence, machine learning, virtual reality, and augmented reality. In terms of AI alone, the potential in savings could be $150 billion annually for the U.S. healthcare economy by 2026. The market’s growth is huge, with expectations that it will reach $6.6 billion by 2021.
At its heart, according to most definitions, virtual health combines clinical care and professional collaboration through telemedicine, telehealth, and collaboration at a distance to connect clinicians, patients, care teams, and health professionals to provide health services, support patient self-management and coordinate care across the care continuum. This is a significant umbrella and a market that analysts predict could range from $13 billion to $17 billion by the end of 2026.
As the population continues to become more and more comfortable with virtual voice assistants, online platforms that allow for one-click consumption, augmented and virtual reality consumer games, and online video chats, the hurdles to adopt virtual care technologies will be significantly lowered.
Furthermore, breakthrough technology enhancements and development are increasing exponentially. For example, at this month’s DPharm meeting in Boston, Unlearn Founder and CEO Charles Fisher revealed a hypothesis as to how digital twins will revolutionize clinical trials. According to Mr. Fisher, a digital twin is a virtual copy, or simulation, of some real object. We are truly entering a new age of discovery.
Taren Grom, Editor
Understanding of the human microbiome and the implications for medicine have openned up a new paradigm of therapy — microbiota-based drug therapies.
Virtual health and digital technology are gaining traction in clinical trials and patient services, and they will continue to shape the industry’s processes in the future.
AI adoption is gathering steam across healthcare but companies say there remains a need for evidence to demonstrate its value.
2020 Year in Preview
The who, what, where, and how of the future of the life-sciences. We ask 20 provocative questions to ellicit an exciting dialogue about the near- and longer-term future of the industry.
Showcase: Supply Chain Management
Volume 19 • Number 9
Publisher Lisa Banket
Editor Taren Grom
Creative Director Marah Walsh
Director of Sales
National Account Manager
Webcast Network Producer
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Nineteen, Number Nine
PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O. Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.
Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.
PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.
Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: firstname.lastname@example.org.
Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: email@example.com.
Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.
Advertising in PharmaVoice: To advertise in PharmaVoice please contact our Advertising Department at P.O. Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: firstname.lastname@example.org.
Send your letters to email@example.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.